Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product.

Damasceno BP, Dominici VA, Urbano IA, Silva JA, Araújo IB, Santos-Magalhães NS, Silva AK, Medeiros AC, Oliveira AG, Egito ES.

J Biomed Nanotechnol. 2012 Apr;8(2):290-300.

PMID:
22515080
2.

Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.

Tang X, Zhu H, Sun L, Hou W, Cai S, Zhang R, Liu F.

Int J Nanomedicine. 2014 Nov 24;9:5403-13. doi: 10.2147/IJN.S71623. eCollection 2014.

3.

Formulation and evaluation of microemulsion based delivery system for amphotericin B.

Darole PS, Hegde DD, Nair HA.

AAPS PharmSciTech. 2008;9(1):122-8. doi: 10.1208/s12249-007-9022-8. Epub 2008 Jan 18.

4.

In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.

Tabosa Do Egito ES, Appel M, Fessi H, Barratt G, Puisieux F, Devissaguet JP.

J Antimicrob Chemother. 1996 Sep;38(3):485-97.

5.

Mixed micellar nanoparticle of amphotericin B and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity.

Han K, Miah MA, Shanmugam S, Yong CS, Choi HG, Kim JA, Yoo BK.

Arch Pharm Res. 2007 Oct;30(10):1344-9.

PMID:
18038914
6.

Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.

Espuelas MS, Legrand P, Campanero MA, Appel M, Chéron M, Gamazo C, Barratt G, Irache JM.

J Antimicrob Chemother. 2003 Sep;52(3):419-27. Epub 2003 Jul 29.

7.

Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.

Gangadhar KN, Adhikari K, Srichana T.

Int J Pharm. 2014 Aug 25;471(1-2):430-8. doi: 10.1016/j.ijpharm.2014.05.066. Epub 2014 Jun 4.

PMID:
24907597
8.

Influence of the freeze-drying process on the physicochemical and biological properties of pre-heated amphotericin B micellar systems.

Siqueira SD, Silva-Filho MA, Silva CA, Araújo IB, Silva AE, Fernandes-Pedrosa MF, Oliveira AG, Egito ES.

AAPS PharmSciTech. 2014 Jun;15(3):612-9. doi: 10.1208/s12249-014-0085-z. Epub 2014 Feb 8.

9.

Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.

Zia Q, Khan AA, Swaleha Z, Owais M.

Int J Nanomedicine. 2015 Mar 5;10:1769-90. doi: 10.2147/IJN.S63155. eCollection 2015.

10.

Structure and toxicity of amphotericin B/triglyceride emulsion formulations.

Lance MR, Washington C, Davis SS.

J Antimicrob Chemother. 1995 Jul;36(1):119-28.

PMID:
8537259
11.

Amphotericin B aggregation inhibition with novel nanoparticles prepared with poly(epsilon-caprolactone)/poly(n,n-dimethylamino-2-ethyl methacrylate) diblock copolymer.

Shim YH, Kim YC, Lee HJ, Bougard F, Dubois P, Choi KC, Chung CW, Kang DH, Jeong YI.

J Microbiol Biotechnol. 2011 Jan;21(1):28-36.

12.

Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles.

Nahar M, Mishra D, Dubey V, Jain NK.

Nanomedicine. 2008 Sep;4(3):252-61. doi: 10.1016/j.nano.2008.03.007. Epub 2008 May 23.

PMID:
18502187
14.

MFAME, N-methyl-N-D-fructosyl amphotericin B methyl ester, a new amphotericin B derivative of low toxicity: relationship between self-association and effects on red blood cells.

Szlinder-Richert J, Mazerski J, Cybulska B, Grzybowska J, Borowski E.

Biochim Biophys Acta. 2001 Sep 3;1528(1):15-24.

PMID:
11514093
15.

Amphotericin B in oil-water lecithin-based microemulsions: formulation and toxicity evaluation.

Brime B, Moreno MA, Frutos G, Ballesteros MP, Frutos P.

J Pharm Sci. 2002 Apr;91(4):1178-85.

PMID:
11948556
16.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
17.

Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.

Charvalos E, Tzatzarakis MN, Van Bambeke F, Tulkens PM, Tsatsakis AM, Tzanakakis GN, Mingeot-Leclercq MP.

J Antimicrob Chemother. 2006 Feb;57(2):236-44. Epub 2005 Dec 16.

18.

Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B.

Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO.

J Lipid Res. 2006 Feb;47(2):260-7. Epub 2005 Nov 28.

19.

Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In Vitro Antifungal Activity.

Casa DM, Carraro TC, de Camargo LE, Dalmolin LF, Khalil NM, Mainardes RM.

J Nanosci Nanotechnol. 2015 Jan;15(1):848-54.

PMID:
26328449
20.

High purity amphotericin B.

Cleary JD, Chapman SW, Swiatlo E, Kramer R.

J Antimicrob Chemother. 2007 Dec;60(6):1331-40. Epub 2007 Oct 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk